<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911427</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1801</org_study_id>
    <nct_id>NCT03911427</nct_id>
  </id_info>
  <brief_title>Oat and Cholesterol</brief_title>
  <official_title>Impact of Oat Product on LDL Cholesterol in Healthy Men and Women With Elevated LDL-cholesterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glycemic Index Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the effect of an oat ingredient provided over 4 weeks on
      serum LDL cholesterol in men and women with elevated LDL-cholesterol compared to a placebo.

      Secondary endpoints are fasting serum total- and HDL-cholesterol, non-HDL-cholesterol,
      triglycerides, glucose, insulin, glycated albumin, HOMA-IR and Framingham risk score
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fasting serum LDL-cholesterol</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>Reduction in mmol/L is a better outcome and &gt;=5% reduction would be significant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum total cholesterol</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>Reduction in mmol/L is a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum HDL cholesterol</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>Increase in mmol/L is a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting non-HDL-cholesterol</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>Reduction in mmol/L is a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting triglycerides</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>Reduction in mmol/L is a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>Reduction in mmol/L is a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>Reduction in mmol/L is a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glycated albumin</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>% reduction is a better outcome. Normal range is 11-17% of total albumin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting HOMA-IR</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>Reduction is a better outcome. Calculated from serum glucose mmol/L and insulin uU/ml. G×I/22.5, where G is fasting serum glucose in mmol/L and I is fasting serum insulin in uU/mL. Less than 1.0 means insulin-sensitive, which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Framingham risk score</measure>
    <time_frame>Baseline vs. Week 4</time_frame>
    <description>Reduction is a better outcome. 10 year risk for cardiovascular disease = total points expressed as % for men and women. Calculated from sex, age, total and HDL cholesterol (mg/dL), systolic blood pressure (mmHg), smoking (yes/no) and diabetes (yes/no) using the equations given on the Framingham Heart Study website.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Elevated LDL Cholesterol</condition>
  <arm_group>
    <arm_group_label>Powder Mix 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oat powder product, mixed with water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Powder Mix 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Brown rice milk powder product, mixed with water</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active oat beverage</intervention_name>
    <description>Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month</description>
    <arm_group_label>Powder Mix 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control rice beverage</intervention_name>
    <description>Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month</description>
    <arm_group_label>Powder Mix 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fasting LDL cholesterol 116-193 mg/dl (3-5 mmol/L)

          2. Males and non-pregnant, non-lactating females 18-65 years

          3. Agree to consume the investigational product three times daily for the duration of the
             study

          4. BMI 18.5 to 39.9 kg/m2

          5. Blood pressure &lt;160/100 mmHg

          6. Fasting triglycerides &lt;4.0 mmol/L

          7. Fasting serum glucose &lt;126mg/dL (&lt;7 mmol/L)

          8. Serum urea and creatinine &lt; 1.8 times upper limit of normal (ULN)

          9. Serum aspartate aminotransaminase (AST), alanine aminotransferase (ALT) and
             gamma-glutamyl transferase (GGT) &lt; 2 times ULN

         10. Hemoglobin &gt; 0.9 times lower limit of normal and &lt; 1.1 times ULN

         11. Have a stable body weight (&lt;7 kg change) over the past 3-months

         12. Absence of health conditions that would prevent fulfillment of study requirements

        Exclusion Criteria:

          1. Pregnancy, breastfeeding or planning to be pregnant

          2. Allergy or sensitivity to study product ingredients

          3. Dislike description of study product

          4. Diet containing ≥15% of energy from saturated fat

          5. Consuming &gt;20g fiber/per 1000 Kcal or &gt;40g fiber/day (including soluble fiber
             supplements)

          6. Consumption of more than 2 drinks of alcohol per day, or more than 14 drinks per week

          7. Extreme dietary habits

          8. Smoking &gt;5 cigarettes or equivalent per day

          9. Use of cholesterol lowering medication or prescription drug or for treating diabetes
             mellitus within 4 weeks of randomization

         10. Active major gastrointestinal disorder

         11. Major trauma or hospitalization for a medical condition or major surgical event within
             6 months of randomization

         12. History of cancer within two years or randomization, except for non-melanoma skin
             cancer

         13. Any condition or substance use which might, in the opinion of the PI, make
             participation dangerous for the participant, lead to poor attendance or compliance or
             affect the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas MS Wolever, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glycemic Index Laboratories, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glycemic Index Laboratories, Inc. 20 Victoria Street, 3rd Floor</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Beverage</keyword>
  <keyword>Beta glucan</keyword>
  <keyword>Fiber</keyword>
  <keyword>Oat</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>LDL</keyword>
  <keyword>Cholesterol</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

